A Double-blind, Randomized, Placebo-controlled, Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-04236921 In Subjects With Crohn's Disease Who Are Anti-tnf Inadequate Responders (Andante)
A Double-blind, Randomized, Placebo-controlled, Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-04236921 In Subjects With Crohn's Disease Who Are Anti-tnf Inadequate Responders (Andante)
This is a proof of concept study to determine the efficacy and safety of a monoclonal antibody with three doses versus placebo. Subjects will be randomized to a treatment and the dose will be delivered subcutaneously twice, 4 weeks apart. All subjects will have moderate to severe refractory Crohn's Disease.
Inclusion Criteria:
Exclusion Criteria:
New York, New York 10021, United States
New York, New York 10065, United States
SugarLand, Texas 77479, United States
Herston, Brisbane, Queensland 4029, Australia
Hilleroed, 3400, Denmark
Koebenhavn NV, 2400, Denmark
Koege, 4600, Denmark
Kolonaki Athens, 106 76, Greece
Budapest, 1125, Hungary
Szeged, 6720, Hungary
Dublin, Dublin 4, Ireland
Dublin, Dublin 7, Ireland
San Giovanni Rotondo Fg, Foggia 71013, Italy
Rome, Province of Rome 00168, Italy